GenScript Biotech reported that its AI-enabled drug discovery business doubled in the first half of 2026, reflecting a fundamental shift in how pharmaceutical companies are adopting artificial intelligence to accelerate the path from computational design to real-world testing. The company's overall revenue grew 27.3% to approximately $404.2 million, while its AI drug discovery segment maintained rapid growth for the third consecutive half-year period, underscoring how critical experimental validation infrastructure has become as AI reshapes drug development workflows.

The acceleration reveals a critical gap in the AI drug discovery ecosystem: designing promising drug candidates computationally is only half the battle. Once AI models propose new molecules or proteins, pharmaceutical companies need specialized labs, automation, and manufacturing expertise to test whether those candidates actually work in biological systems. GenScript has positioned itself as the bridge between AI prediction and experimental reality, offering what executives call a "Gene-to-Protein platform" that combines gene synthesis, protein production, antibody discovery, and biologics development in a single integrated workflow.

Why Are Pharma Companies Suddenly Investing in Validation Infrastructure?

The surge in demand reflects a maturing AI drug discovery market. Early-stage AI biotech companies and established pharmaceutical firms are moving beyond proof-of-concept projects and scaling up their computational pipelines. As the number and complexity of AI-designed drug candidates increase, so does the need for reliable, fast, and scalable ways to test them. GenScript's adjusted operating profit jumped 102.8% year-over-year, suggesting that this validation infrastructure is not only in high demand but also increasingly profitable.

The company's Gene-to-Protein segment accounted for approximately 66% of total segment revenue and remained the primary growth engine. This business line benefits from what GenScript describes as "deeper engagement with AI drug discovery companies and increasing demand for protein engineering, biologics discovery, and development services." In other words, AI-focused biotech startups and pharmaceutical innovators are choosing GenScript to handle the experimental work that validates their computational predictions.

How Are Companies Leveraging GenScript's Integrated Approach?

• Reduced Coordination Overhead: Instead of managing multiple specialized service providers for gene synthesis, protein production, and antibody discovery, customers work with a single integrated platform that connects all these capabilities in a streamlined workflow.
• Faster Turnaround Times: GenScript continues to invest in global discovery and manufacturing capacity, automation, and digital workflows to shorten the time between computational design and experimental results, enabling customers to validate more candidates quickly.
• Scalability for Complex Programs: As AI-driven customer projects grow increasingly complex, GenScript's infrastructure improvements enhance consistency and allow the company to support larger, more ambitious drug discovery programs without bottlenecks.

The company's CEO emphasized the strategic importance of this positioning. "We see significant long-term opportunity as AI reshapes life sciences and increases demand for experimental validation and development services," stated Sherry Shao, Rotating CEO of GenScript. "By expanding our global Gene-to-Protein platform, automation, digital manufacturing, and delivery network, we are strengthening GenScript's role as a critical infrastructure partner for AI-enabled drug discovery".

"Our first-half results reflect strong execution across the portfolio, with our core businesses driving both revenue growth and improved profitability. We see significant long-term opportunity as AI reshapes life sciences and increases demand for experimental validation and development services," said Sherry Shao, Rotating CEO of GenScript.

Sherry Shao, Rotating CEO of GenScript Biotech Corporation

The broader context matters here. The recovery in global biopharmaceutical research activity, combined with the expanding use of AI, is creating a surge in the number and complexity of drug programs moving from computational design into experimental validation, development, and production. This shift is fundamentally changing how drug discovery works: instead of starting with wet-lab experiments and working backward to understand biology, companies are now starting with AI predictions and working forward to validate them experimentally.

What Does This Mean for the Future of Drug Development?

GenScript's financial performance suggests that the pharmaceutical industry is betting heavily on this new model. The company's adjusted net profit surged 203.3% to approximately $62.5 million, and adjusted gross profit climbed 46.1% to approximately $184.5 million. These metrics indicate that validation and infrastructure services are not just growing in volume but also becoming more profitable, which typically signals a maturing market with strong competitive advantages for established players.

Looking ahead, GenScript expects higher demand, increased utilization across its global network, and further operating leverage to support continued revenue growth and profitability improvement. The company is investing in technology, automation, and capacity to support larger and more complex AI-enabled drug discovery programs. Additionally, GenScript's subsidiary ProBio is expected to achieve positive adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) by 2027, suggesting that the validation and manufacturing infrastructure business is moving toward sustainable profitability.

The doubling of GenScript's AI drug discovery business in a single year is not just a financial milestone; it signals a fundamental reorganization of how pharmaceutical innovation works. As AI becomes better at predicting which molecules might work as drugs, the bottleneck shifts from computational design to experimental validation. Companies like GenScript that can provide fast, reliable, and scalable infrastructure for testing those predictions are positioning themselves as essential partners in the next generation of drug development.